Roivant Sciences’ (ROIV) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Roivant Sciences (NASDAQ:ROIV) in a research note issued to investors on Wednesday morning,Benzinga reports. The firm currently has a $18.00 price objective on the stock.

Other equities research analysts have also issued research reports about the stock. Bank of America increased their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research note on Wednesday, September 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $17.39.

Roivant Sciences Stock Performance

Shares of Roivant Sciences stock opened at $11.95 on Wednesday. The firm has a market cap of $8.84 billion, a PE ratio of 2.12 and a beta of 1.24. The firm’s 50-day simple moving average is $11.78 and its 200-day simple moving average is $11.31. The company has a debt-to-equity ratio of 0.05, a quick ratio of 27.91 and a current ratio of 27.91. Roivant Sciences has a 1 year low of $8.56 and a 1 year high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). The company had revenue of $4.48 million during the quarter, compared to analyst estimates of $34.57 million. Roivant Sciences had a net margin of 3,827.42% and a negative return on equity of 14.65%. Equities analysts forecast that Roivant Sciences will post -1.14 earnings per share for the current fiscal year.

Insider Buying and Selling at Roivant Sciences

In other news, COO Eric Venker sold 100,000 shares of the stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $11.65, for a total value of $1,165,000.00. Following the completion of the transaction, the chief operating officer now directly owns 617,470 shares in the company, valued at $7,193,525.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO Matthew Gline sold 1,983,257 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $11.79, for a total value of $23,382,600.03. Following the completion of the transaction, the chief executive officer now directly owns 17,870,543 shares in the company, valued at $210,693,701.97. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Eric Venker sold 100,000 shares of the stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the completion of the transaction, the chief operating officer now owns 617,470 shares of the company’s stock, valued at $7,193,525.50. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 3,577,309 shares of company stock worth $42,151,184. 7.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ROIV. nVerses Capital LLC purchased a new stake in shares of Roivant Sciences in the 2nd quarter valued at approximately $34,000. Gladius Capital Management LP purchased a new stake in shares of Roivant Sciences in the 3rd quarter valued at approximately $35,000. Point72 Hong Kong Ltd purchased a new stake in shares of Roivant Sciences in the 2nd quarter valued at approximately $36,000. US Bancorp DE lifted its position in shares of Roivant Sciences by 146.5% in the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after acquiring an additional 1,948 shares in the last quarter. Finally, Quarry LP purchased a new stake in shares of Roivant Sciences in the 2nd quarter valued at approximately $53,000. 64.76% of the stock is currently owned by institutional investors.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.